Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohortsEnrollment in the Phase 1b/2 multiple-ascending dose trial of TH103
Kalaris is sharing more test results from a medicine called TH103 that might help people with eye problems, and the new results look similar to earlier ones. When a company shares positive test results and stays on schedule, it's a sign the medicine might work, but we won't know for sure until more testing is done.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.